Screener / SEC EDGAR /CIK 0001668397 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Research Services

Medpace Holdings, Inc. MEDP

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of MEDP's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Aug 19, 2019
Questions asked 58 each answered in the company's own letter
No closing letter 4 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 10 UPLOAD
  2. 2. Questions in them 58 numbered comments
  3. 3. Company replies 10 CORRESP
  4. 4. Reviews closed 1 of 5 closing letter

Half the closed reviews took 14 days or less from the first letter to the closing letter.

Schedule 14D-9

2019-08-19 to 2019-08-19 · 3 questions · 1 letter from the SEC, 0 from the company
No closing letter
SEC letter of Aug 19, 2019 ↗ no reply letter on EDGAR
Schedule 14D-9 · Item 4
SEC asked (1)
Please revise to provide further detail about why Medpace Holdings is not making a recommendation to Eligible Option Holders. It is true in the case of any tender offer that whether to participate is based in part on each holder’s personal situation.
Rest of the question

Please expand to explain what specifically about this offer by an affiliate of the Company informed the Board’s decision not to make a recommendation to subject security holders.

MEDP answered

No reply letter found.

Schedule 14D-9 · Item 4
SEC asked (2)
See our last comment above. Summarize the deliberations at the meeting cited in subparagraph (b) of this section, including the Board’s consideration of “numerous factors” leading up to its determination with respect to the Offer.
MEDP answered

No reply letter found.

General
SEC asked (3)
In your response letter, indicate how you disseminated the Schedule 14D-9 and how you intend to disseminate the revisions made in response to comments above.
MEDP answered

No reply letter found.

Schedule TO-T/A

2019-08-13 to 2019-08-20 · 15 questions · 2 letters from the SEC, 0 from the company
No closing letter
Income taxesRisk factors
SEC letter of Aug 13, 2019 ↗ no reply letter on EDGAR
General
SEC asked (1)
Given the nature of the comments below and the resulting significant changes to the structure and disclosure associated with the offer, we believe it may be appropriate to disseminate a revised offer document to Eligible Option holders in the same manner as was the original Offer to Purchase. In your response letter, please tell us how you will disseminate the amended offer materials.
MEDP answered

No reply letter found.

General
SEC asked (2)
As discussed with you previously, this offer is not eligible to rely on the “global relief” letter issued by the Division of Corporation Finance for issuer employee stock option exchange offers. See Issuer Exchange Offers Conducted for Compensatory Purposes (March 21, 2001). Therefore, please revise your offer to fully comply with the provisions of Rule 14d-10.
MEDP answered

No reply letter found.

How was the value of each Eligible Option determined?, page 2
SEC asked (3)
Explain how you chose the $55.00 reference point in calculating the amount to be paid per tendered option, when the most recent trading price of the Company’s common stock on NASDAQ Global Select Market immediately before this offer commenced was $76.70 per share.
MEDP answered

No reply letter found.

U.S Federal Income Tax Consideration, page 6
SEC asked (4)
You state that the cash payment for tendered Eligible Options will be treated as compensation by the Company and the tendering holder will recognize ordinary income reflected on his or her Form W-2 issued by Medpace. In your response letter, with a view to further disclosure, explain how this is the case, since the bidders and not the Company will make payment for the tendered Eligible Options.
Rest of the question

See Item 4 of Schedule TO and Item 1004(a)(1)(xii) of Regulation M-A.

MEDP answered

No reply letter found.

Risk Factors, page 7
SEC asked (5)
Revise the first or second risk factors to expressly note that the reference payment price of $55.00 per common share is over $21 less than the most recent trading price of the common shares underlying these options. While the existing risk factors hint at possible risks, we do not believe the immediate existing risk upon tender based on the most recent stock trading price is clearly articulated.
MEDP answered

No reply letter found.

Conditions of the Offer, page 13
SEC asked (6)
In condition (c)(i), explain what it meant by a “limitation on prices for securities on any national securities exchange or in the over-the-counter market.”
MEDP answered

No reply letter found.

Interests of Directors and Executive Officers; Transactions and Arrangements Concerning · Eligible Options, page 16
SEC asked (7)
Revise this section to include a discussion of Mr. Troendle’s interests in the offer as a bidder for the Eligible Options.
MEDP answered

No reply letter found.

Source and Amount of Funds; Status of Eligible Options Tendered in the Offer; Accounting · Consequences of the Offer, page 16
SEC asked (8)
We note that you have revised the offer documents to reflect that Mr. Troendle and Medpace Investors LLC rather than the Company are purchasing tendered Eligible Options. However, the disclosure about the source of funds used to purchase tendered securities has not changed from when this offer was filed as an issuer tender offer.
Rest of the question

The bidders in this offer are an individual and a limited liability company he controls. The total proceeds needed to purchase tendered Eligible Options exceed $33,000,000. In addition, as the offer is currently structured, bidders fall outside the safe harbor outlined in Instruction 2 to Item 10 of Schedule TO relating to the need to provide financial statements for the bidders in this offer. Please revise this section to explain in greater detail the source of the funds to be used to purchase tendered Eligible Options. In your response letter, explain why you believe bidders’ financial statements are not material in the context of this offer.

MEDP answered

No reply letter found.

Source and Amount of Funds; Status of Eligible Options Tendered in the Offer; Accounting · Consequences of the Offer, page 16
SEC asked (9)
Briefly describe the accounting consequences of the offer. See Item 4 of Schedule TO and Item 1004(a)(1)(xi) of Regulation M-A.
MEDP answered

No reply letter found.

Information Concerning Medpace, Medpace Holdings and Medpace Investors, page 18
SEC asked (10)
This section should be revised to include all of the disclosure required by Item 1003(a)- (c) for each filing person on the Schedule TO and all of the affiliated persons captured by General Instruction C to Schedule TO.
MEDP answered

No reply letter found.

Information Concerning Medpace, Medpace Holdings and Medpace Investors, page 18
SEC asked (11)
The disclosure included under Item 5 of the Schedule TO should be provided in the disclosure document disseminated to target option holders. See Item 1005(a) and (b) of Regulation M-A.
MEDP answered

No reply letter found.

Information Concerning Medpace, Medpace Holdings and Medpace Investors, page 18
SEC asked (12)
State the purpose of the offer and the current plans of the bidders with respect to the options acquired in this offer. See Item 1006(a)-(c) of Regulation M-A and Item 6 of Schedule TO. Your revised disclosure should include a discussion of the reasons for structuring the offer in this manner (with a third party, affiliated bidder) and the impact
MEDP answered

No reply letter found.

Information Concerning Medpace, Medpace Holdings and Medpace Investors, page 18
SEC asked (13)
The information about the interest of the bidders in the subject securities (including the underlying common stock) must be included in the disclosure document disseminated to shareholders (not just in the Schedule TO). See Item 1008 of Regulation M-A and Item 8 of Schedule TO. Please revise.
MEDP answered

No reply letter found.

SEC letter of Aug 20, 2019 ↗ no reply letter on EDGAR
General
SEC asked (1)
Refer to comment 2 in our prior comment letter dated August 13, 2019. On page 8 of the revised Offer to Purchase, you state that options to purchase 921,896 shares of Medpace Holdings are issued and outstanding under the 2014 Plan.
Rest of the question

You further state that “[o]f the outstanding options, options to purchase 876,533 shares of common stock are Eligible Options with respect to the Offer.” Since the Offer must comply with the all-holders provisions of Rule 14d-10(a)(1), explain which options are excluded and why. Your response letter should provide an analysis of how exclusion of these options is consistent with the requirements of Rule 14d-1(a)(1).

MEDP answered

No reply letter found.

Information Concerning Medpace, Medpace Holdings and Medpace Investors
SEC asked (2)
Refer to comment 10 in our last comment letter and the revised disclosure included here in response to that comment. As requested, this section should be revised to include all of the disclosure required by Item 1003(a)-(c) for each filing person on the Schedule TO and all of the affiliated persons captured by General Instruction C to Schedule TO.
Rest of the question

The revised disclosure should identify the “other members of Medpace Investors” besides Mr. Troendle. Currently, you identify them as “the executive officers of Medpace Holdings and other employees of Medpace and subsidiaries of Medpace.” Once these individuals are identified, please ensure that all of the disclosure required by Item 1003(a)-(c) is provided as to each.

MEDP answered

No reply letter found.

Form 10-K

2019-07-26 to 2019-08-09 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2019-08-09
Controls
SEC asked
It appears your officer certifications filed under Exhibits 31.1 and 31.2 do not include the language referring to internal control over financial reporting that should appear in the introductory sentence of paragraph 4 of the Section 302 certifications.
Rest of the question

Please note this additional language became effective for your first annual report required to contain management’s report on internal control over financial reporting and in all periodic reports filed thereafter. Please revise your filings to include the correct certifications. We refer you to the guidance under Compliance and Disclosure Interpretations (C&DI) for Regulation S-K, Question 246.13. This comment is also applicable to your Form 10-Q for fiscal quarter ended March 31, 2019.

MEDP answered
As requested, beginning with its

Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and in future periodic reports, Medpace will include the required language referring to internal control over financial reporting in the introductory sentence of paragraph 4 of the

Section 302 certifications.

* * * * * * * * * * * *

We trust that the foregoing sufficiently addresses your comments. We appreciate any opportunity to discuss any comments or questions you may have in advance of any written response the staff may intend to provide in connection with the above.
Rest of the answer

If there is a need for additional information or clarification, please contact me at (513) 579-6469.

Read in the reply

Also in this review: closing letter, 2019-08-09

Form S-3

2017-09-18 to 2017-10-18 · 3 questions · 2 letters from the SEC, 3 from the company
No closing letter
Debt
Description of Purchase Contracts, page 28
SEC asked (1)
We note your disclosure that you may issue purchase contracts for the purchase or sale of debt or equity securities issued by third parties or “a basket of such securities, an index or indices or such securities or any combination of the above as specified in the applicable prospectus supplement.” We also note that you may issue purchase contracts for the purchase or sale of currencies or commodities.
Rest of the question

Please advise us how you anticipate conducting such offerings under the registration and disclosure requirements of the Securities Act. For example, please advise us of the disclosure you will provide in the applicable prospectus supplement or other offering materials, including, as necessary, any required financial statement and non-financial statement disclosure about the issuer of such securities. For guidance, please refer to the Morgan Stanley & Co., Inc. no-action letter (June 24, 1996) and Securities Act Sections Compliance and Disclosure Interpretation 203.03.

MEDP answered
The Company confirms to the Staff that, in connection with any issuance by the Company of purchase contracts for the purchase or sale of debt or equity securities issued by third parties or a basket of such securities, an index or indices or such securities or any combination of the above as specified in the applicable prospectus supplement, it (i) will comply with the registration and disclosure requirements of the Securities Act and any other applicable rules and regulations in effecting the distribution of any such purchase contracts and (ii) will include disclosure as necessary in the
Rest of the answer

applicable prospectus supplement or other offering materials, including any required financial statement and non-financial statement disclosure about the issuer of such third-party debt obligations, all as consistent with the Morgan Stanley & Co., Inc. no-action letter (June 24, 1996) and Securities Act Sections Compliance and Disclosure Interpretation 203.03. Additionally, the Company acknowledges the

Staff’s comment and confirms that it does not wish to issue purchase contracts for the purchase or sale of currencies or commodities. Accordingly, the Company has revised its disclosure on page 28 of the Registration Statement in response to the Staff’s comment to remove references to contracts for the purchase or sale of currencies or commodities.

Read in the reply
Description of Purchase Contracts, page 28
SEC asked (2)
It is not clear how the purchase contracts you propose to issue should be characterized for purposes of the federal securities laws. For example, the disclosure in the filing indicates that these contracts may obligate you to sell to holders of these contracts and for holders of these contracts to purchase securities at a specified purchase price.
Rest of the question

The disclosure in the filing also indicates that these contracts may require you to make periodic payments to the holders of the contracts or for holders of these contracts to make periodic payments to you. Finally, the disclosure in the filing indicates that these contracts may require the holders of the contracts to secure their obligations in a specified manner. Based on this disclosure it appears that these contracts may have characteristics associated with forwards, options and security-based swaps. Please provide us with your legal analysis as how these contracts should be appropriately characterized under the federal securities laws.

MEDP answered
The Company respectfully notes that because the Registration Statement seeks to register purchase contracts with respect to the future delivery of “debt or equity securities issued by us or securities of third parties, a basket of such securities, an index or indices or such securities or any combination of the above as specified in the applicable prospectus supplement” under the Registration Statement, the Company respectfully submits that the purchase contracts are properly characterized as either “investment contracts” as that term is used in

Section 2(a)(1) of the Securities Act or
Rest of the answer

“security forwards” as defined in the Commission’s Release No. 33-9338; 34-67453 (dated August 13,

2012), and further submits that such purchase contracts should be properly excluded from the definition of “swap” under Section 1a(47)(B) of the Commodity Exchange Act and from the definition of “security-based swap” under

Section 2(a)(17) of the Securities Act, Section 1a(42) of the Commodity Exchange Act and Section 3(a)(68) of the Securities Exchange Act of 1934, as amended. The Company has also revised its disclosure on page 28 of the Registration

Statement in response to the Staff’s comment.

We hope that the foregoing has been responsive to the Staff’s comment and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at (212) 906-2918 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.

Read in the reply
Description of Purchase Contracts, page 28
SEC asked
Please refer to prior comment 2. It is not clear how you concluded the purchase contracts should be properly excluded from the definition of security-based swap under Section 2(a)(17) of the Securities Act 1933 and Section 3(a)(68) of the Securities Exchange Act of 1934, as the definition of purchase contracts as described in the offering appears sufficiently broad as to include security-based swaps.
Rest of the question

It appears the purchase contracts could include transactions that are not excluded under Section 1a(47)(B) of the Commodity Exchange Act but otherwise fall within the definition of a security-based swap. Please provide an expanded legal analysis that addresses clearly how the purchase contracts as defined do not include security-based swaps.

MEDP answered
The

Company respectfully advises the Staff that it has decided not to offer purchase contracts through the Registration Statement and has updated the Registration Statement accordingly to remove references to purchase contracts.

We hope that the foregoing has been responsive to the Staff’s comment and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at (212) 906-2918 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.
Read in the reply

Also in this review: company letter, Oct 18, 2017

Form S-1

2016-04-11 to 2016-08-08 · 36 questions · 4 letters from the SEC, 6 from the company
No closing letter
Liquidity and cashResults discussion (MD&A)RevenueRisk factorsDebtGoodwill and impairmentSegmentsInventoryAcquisitionsLeasesNon-GAAP measures
SEC letter of Apr 11, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
MEDP answered

No reply letter found.

Summary, page 1
SEC asked (2)
To provide context and a balanced discussion of your “strong financial performance,” “industry-leading margins” and other competitive advantages, please revise the Summary to address your debt and historic net losses in qualitative and quantitative terms.
MEDP answered

No reply letter found.

Summary, page 1
SEC asked (3)
Please revise the discussion of “The Transaction” to clarify the parties, purpose and result in plain English. Currently the legalistic discussion of merger subsidiaries and other details is difficult to understand after one reading.
MEDP answered

No reply letter found.

Risk Factors, page 18
SEC asked (4)
Please revise risk factors to address the provision in your charter renouncing any interest or expectancy that you have in business opportunities as discussed in the last paragraph on page 117.
MEDP answered

No reply letter found.

Risk Factors, page 18
SEC asked (5)
Please revise the risk factor “Covenant restrictions under our Senior Secured Credit Facilities …” on page 35 to quantify the financial ratio restrictions.
MEDP answered

No reply letter found.

Risk Factors, page 18
SEC asked (6)
Please disclose the “certain of these exemptions” in the last risk factor on page 37 or indicate that the company has not yet determined which exemptions to utilize.
MEDP answered

No reply letter found.

Use of Proceeds, page 45
SEC asked (7)
We note your disclosure on page 45 regarding the interest rate on the Senior Secured Term Loan Facility. Please revise parts (a) and (b) of the interest rate term description to accurately reflect the leverage ratio thresholds used to determine the spread.
MEDP answered

No reply letter found.

Use of Proceeds, page 45
SEC asked (8)
Please provide the maturity and use of indebtedness disclosure per Instruction 4 to Item 506.
MEDP answered

No reply letter found.

Capitalization, page 47
SEC asked (9)
You disclose on page 45 that a portion of the offering proceeds will be used to repay borrowings under your Senior Secured Term Loan Facility. Please disclose the pro forma effects of this repayment on your net (loss) income and net (loss) income per share for the year ended December 31, 2015 and describe how the pro forma effect was computed.
MEDP answered

No reply letter found.

Key Performance Metrics · New Business Awards, Cancellations and Backlog, page 57
SEC asked (10)
We note the discussion of cancellations as a key performance metric. Please revise to address, and quantify where material, the variability of cancellation rates for the periods presented. We note the statement on page 18 that the cancellation rate was 3.2% for the quarter ended December 31, 2015.
MEDP answered

No reply letter found.

Liquidity and Capital Resources, page 65
SEC asked (11)
We note the statements at the bottom of page 65 qualifying your belief that you have sufficient liquidity to finance operations for at least the next 12 months. Please revise to address liquidity on both a shortand long-term basis and clarify any known trends or uncertainties that you believe are reasonably likely to result in liquidity decreasing in a material way. See Instruction 5 to Item 303(a).
MEDP answered

No reply letter found.

Business · Our Market, page 79
SEC asked (12)
We note your reference on page 80 to financial data available from FactSet Research Systems Inc. as of September 30, 2015, with respect to companies comprising the NASDAQ Biotechnology Index. Please provide a copy of the report containing this data and confirm whether you commissioned the report.
MEDP answered

No reply letter found.

Our Competitive Strengths, page 81
SEC asked (13)
We note the page 82 reference to the Avoca Group’s 2011 Avoca Survey on Clinical Outsourcing Practices. Please clarify whether you believe you are among the “top 5 CROs by revenue” and advise us of the extent to which more updated data are available.
MEDP answered

No reply letter found.

Our Growth Strategy, page 83
SEC asked (14)
Please revise the discussion of organic growth on page 83 to explain and differentiate the significant amount of goodwill, as disclosed on page 29.
MEDP answered

No reply letter found.

Our Growth Strategy, page 83
SEC asked (15)
Please revise to address the nature and extent of your business associated with “risk sharing arrangements” referenced on page 30.
MEDP answered

No reply letter found.

Competition, page 89
SEC asked (16)
Please revise to address the positive and negative factors pertaining to your competitive position with respect to the principal methods of competition. In this regard, we note the discussion of your competitive strengths in the Summary, for example your “industryleading margins (compared to our public competitors)” and “differentiated operating model.” Please revise accordingly. See Item 101(c)(x) of Regulation S-K.
MEDP answered

No reply letter found.

Government Regulation, page 89
SEC asked (17)
Where you discuss INDs, IRBs and other material regulations, please revise to clarify the extent to which you are directly subject to the requirements as compared to being partially or entirely exempt from regulations because you merely provide third party services to the regulated applicant.
MEDP answered

No reply letter found.

Executive and Director Compensation, page 100
SEC asked (18)
We note that you have disclosed in Note 10 to the financial statements that you have granted stock options and restricted shares during the year ended December 31, 2015. Please advise why you do not include tables pursuant to Item 402(d) and 402(g) of Regulation S-K.
MEDP answered

No reply letter found.

Certain Relationships and Related Person Transactions, page 108
SEC asked (19)
Please revise to include a description of all related person transactions. In this regard, we note from page F-36 that you extended short term loans to employees. We also note from page F-39 that an employee entered into a stock purchase agreement permitting the purchase of 50,000 shares of your common stock at the then-current value for those shares. Please revise accordingly.
MEDP answered

No reply letter found.

Certain Relationships and Related Person Transactions, page 108
SEC asked (20)
Please disclose Dr. Troendle’s indirect and direct, if any, ownership interest in Coherus.
MEDP answered

No reply letter found.

Certain Relationships and Related Person Transactions, page 108
SEC asked (21)
Please disclose the basis on which Cinven is a related person.
MEDP answered

No reply letter found.

Consolidated Balance Sheets, page F-3 · Consolidated Statements of Cash Flows, page F-7
SEC asked (22)
Please disclose the amount of inventory as of each balance sheet date. Please also present changes in inventory during each period separately in your consolidated statements of cash flows. See Rule 5-02.6 of Regulation S-X and ASC 230-10-45-29.
MEDP answered

No reply letter found.

Consolidated Balance Sheets, page F-3 · Consolidated Statements of Cash Flows, page F-7
SEC asked (23)
Please revise your cash flows from operating activities section to present changes in other assets separately from changes in other liabilities, rather than netting these amounts. Notes to Consolidated Financial Statements 2. Change in Control, page F-8
MEDP answered

No reply letter found.

Consolidated Balance Sheets, page F-3 · Consolidated Statements of Cash Flows, page F-7
SEC asked (24)
If expenses contingent upon the change-in-control event were incurred, please disclose the nature and amounts recorded in the predecessor period, successor period and “on the line.” Please also disclose your basis for determining the amounts included in each category.
MEDP answered

No reply letter found.

Consolidated Balance Sheets, page F-3 · Consolidated Statements of Cash Flows, page F-7
SEC asked (25)
Please revise to provide a qualitative description of the factors that make up the goodwill recognized as required by ASC 805-30-50-1(a). 3. Summary of Significant Accounting Policies
MEDP answered

No reply letter found.

Reportable Segments, page F-11
SEC asked (26)
On page 85, you discuss your various service offerings. You also disclose here that your CODM assesses your revenue by service offering. Please disclose your revenues for each type of service or group of similar services offered for each period presented. See ASC 280-10-50-40.
MEDP answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (27)
You disclose that most contracts are terminable by the customer, either immediately or according to advance notice terms. Please tell us the general terms of early termination specified in your contracts, including the method used to compute amounts due upon settlement.
Rest of the question

Please also tell us how the method generally used to compute the early termination amounts due upon settlement differs from the method used for revenue recognition on contracts not being terminated. Please disclose the nature of any material differences.

MEDP answered

No reply letter found.

Exhibits
SEC asked (28)
Please include a complete exhibit index. As non-exclusive examples, it is unclear why the index does not identify the Voting Agreement, lease agreements, and the new credit agreement referenced in footnote 1 on page 10.
MEDP answered

No reply letter found.

SEC letter of May 6, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
We note the free cash flow numbers for 2014 and 2015 on page 18. Please advise us regarding the reasons for different numbers on page 31 of the materials provided in response to comment 1.
MEDP answered

No reply letter found.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (2)
Please revise or advise us why you do not separately address your labs unit, which appears to be a material part of your operations as presented in the materials provided in response to comment 1.
MEDP answered

No reply letter found.

Business, page 81
SEC asked (3)
We note your response to comment 15. Please revise here or where appropriate to indicate, as explained in your response, that you expect the use of risk sharing arrangements to be very limited and that they are not a part of your core growth strategy.
MEDP answered

No reply letter found.

Business, page 81
SEC asked (4)
We note the revised disclosure in response to comment 17 and the reference to GCP as one example of regulations directly applicable to you. Please revise to clarify the extent to which regulations on the following are generally directly applicable to you: “the approval process, manufacturing, safety, labeling, storage, record keeping and marketing.”
MEDP answered

No reply letter found.

Executive and Director Compensation, page 103
SEC asked (5)
We note that you have disclosed compensation only for fiscal year 2015 in the Summary Compensation Table. Please advise why you do not include compensation for fiscal year 2014 pursuant to Item 402(n) of Regulation S-K.
MEDP answered

No reply letter found.

Note 3. Summary of Significant Accounting Policies · Reportable Segments, page F-11
SEC asked (6)
We read your response to comment 26. Your CODM assesses your revenue, backlog and net awards by service offering. Please tell us in detail the nature of each of these service offerings and describe for us the differences between each service offering. Please also tell us why the CODM separately assesses the revenues of each service offering.
Rest of the question

Alternatively, please disclose your revenues for each type of service or group of similar services offered for each period presented. See ASC 280-10-50-40.

MEDP answered

No reply letter found.

Business · Our Services, page 94
SEC asked
We note your response to comment 2. Please revise pages 94-96 to (1) more clearly address your laboratory services, including the difference between laboratory only offerings and services performed as “a component of a full service clinical development arrangement,” and (2) indicate, consistent with your response, that laboratory only services are immaterial.
MEDP answered
The Company respectfully acknowledges the Staff’s comment and has revised its disclosure on page 96 of the Registration

Statement accordingly.

We hope that the foregoing has been responsive to the Staff’s comment and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at (212) 906-2918 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.
Read in the reply
Form S-1 Filed June 24, 2016 · Consolidated Financial Statements, page F-1
SEC asked
Please revise your historical financial statements to give retrospective effect to the reverse stock split that you expect to effectuate prior to the effectiveness of this registration statement. If your auditors believe that only a draft report can be presented due to a pending future event, such as the reverse stock split, they should include in the filing a signed and dated preface to their draft report stating
Rest of the question

the reason for the draft report and that they expect to be in a position to issue the report in the form presented prior to effectiveness. A signed, dated and unrestricted auditor’s report must be included in the filing prior to effectiveness. Refer to SAB Topic 4:C and Rule 2-02 of Regulation S-X.

MEDP answered
Reference is made to the telephonic discussion on June 21, 2016 among representatives of the Staff (the

“Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission, Medpace Holdings, Inc. (the “Company”) and Latham & Watkins regarding the Company’s testing the waters materials provided to the Staff supplementally on June 14, 2016.
Rest of the answer

In response to the Staff’s question regarding slide 8, the Company confirms to the Staff that the information on slide 8 conforms to the information in Figure 7 on page 12 of the Citeline Pharma R&D Annual Review 2016 source (the “Citeline Source”), other than the omission of the information for the Biotechnology and Reformulations categories. The Company notes that this information was omitted from slide 8 because the categories Biotechnology and Reformulations are not therapeutic areas, but rather are broader categories that could include drugs under development across different therapeutic areas. *. Therefore, the Company omitted this information from slide 8 since it would not be meaningful to an investor given the Company’s focus on its core therapeutic areas. The Company intends to update its disclosure on slide 8 and has updated its disclosure in the

Registration Statement to note that its core therapeutic expertise covers the therapeutic areas where a majority of all drugs are currently in development, rather than over 70%.

The Company respectfully requests that the information contained in this request letter be treated as confidential information and that the Commission provide timely notice to Dr. August J. Troendle, President and Chief Executive Officer, Medpace Holdings, Inc., 5375 Medpace Way, Cincinnati, Ohio 45227, telephone

(513) 579-9911, before it permits any disclosure of the underlined and highlighted information contained in this request letter.

Read in the reply

Also in this review: company letter, Jul 1, 2016, company letter, Jul 28, 2016, company letter, Aug 8, 2016, company letter, Aug 8, 2016

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 21 letters filed since 2016-04-12. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MEDP/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.